BR112016008979A2 - - Google Patents

Info

Publication number
BR112016008979A2
BR112016008979A2 BR112016008979A BR112016008979A BR112016008979A2 BR 112016008979 A2 BR112016008979 A2 BR 112016008979A2 BR 112016008979 A BR112016008979 A BR 112016008979A BR 112016008979 A BR112016008979 A BR 112016008979A BR 112016008979 A2 BR112016008979 A2 BR 112016008979A2
Authority
BR
Brazil
Application number
BR112016008979A
Other languages
Portuguese (pt)
Other versions
BR112016008979B1 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112016008979A2 publication Critical patent/BR112016008979A2/pt
Publication of BR112016008979B1 publication Critical patent/BR112016008979B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
BR112016008979-0A 2013-10-22 2014-10-22 Composições farmacêuticas compreendendo agentes antibacterianos e seus usos BR112016008979B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3309/MUM/2013 2013-10-22
PCT/IB2014/065522 WO2015059643A1 (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
IN3309MU2013 IN2013MU03309A (enExample) 2013-10-22 2014-10-22

Publications (2)

Publication Number Publication Date
BR112016008979A2 true BR112016008979A2 (enExample) 2017-08-01
BR112016008979B1 BR112016008979B1 (pt) 2023-04-25

Family

ID=52003012

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016008979-0A BR112016008979B1 (pt) 2013-10-22 2014-10-22 Composições farmacêuticas compreendendo agentes antibacterianos e seus usos

Country Status (18)

Country Link
US (1) US9827235B2 (enExample)
EP (1) EP3060213B1 (enExample)
JP (2) JP2016538258A (enExample)
KR (1) KR102340010B1 (enExample)
CN (2) CN106102741A (enExample)
AU (1) AU2014338612C1 (enExample)
BR (1) BR112016008979B1 (enExample)
CA (1) CA2928364C (enExample)
DK (1) DK3060213T3 (enExample)
ES (1) ES2902456T3 (enExample)
HU (1) HUE057504T2 (enExample)
IN (1) IN2013MU03309A (enExample)
MX (1) MX375934B (enExample)
NZ (1) NZ719215A (enExample)
PL (1) PL3060213T3 (enExample)
PT (1) PT3060213T (enExample)
RU (1) RU2702361C2 (enExample)
WO (1) WO2015059643A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107580595B (zh) * 2015-05-07 2020-09-18 拜欧蒂姆公司 杂环化合物及它们在预防或治疗细菌感染中的应用
CN109310682A (zh) * 2016-06-17 2019-02-05 沃克哈特有限公司 抗菌组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465428B1 (en) * 1999-08-27 2002-10-15 Aventis Pharma S.A. Pharmaceutical combinations based on dalfopristine and quinupristine, and on cefepime
MX2007007235A (es) * 2004-12-17 2007-10-19 Venus Remedies Ltd Combinacion de antibioticos para proporcionar una solucion total al tratamiento de infecciones.
RU2366450C1 (ru) * 2008-08-04 2009-09-10 Валентина Васильевна Малиновская Средство для лечения тяжелых инфекционных заболеваний и смешанных инфекций
CA2842777C (en) * 2011-07-26 2015-12-29 Wockhardt Limited Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
BR112013028813B1 (pt) * 2011-08-27 2020-10-20 Wockhardt Limited derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e composições farmacêuticas que os compreendem
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
HUE046893T2 (hu) * 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
AU2014206087A1 (en) * 2013-01-14 2015-05-28 Wockhardt Limited Compositions and methods for treating bacterial infections

Also Published As

Publication number Publication date
CN113577084A (zh) 2021-11-02
IN2013MU03309A (enExample) 2015-07-17
AU2014338612B2 (en) 2019-12-19
PL3060213T3 (pl) 2022-02-14
US20160303104A1 (en) 2016-10-20
KR20160072254A (ko) 2016-06-22
DK3060213T3 (da) 2022-01-03
WO2015059643A1 (en) 2015-04-30
RU2016115376A (ru) 2017-11-28
NZ719215A (en) 2020-04-24
KR102340010B1 (ko) 2021-12-16
PT3060213T (pt) 2021-12-24
CA2928364A1 (en) 2015-04-30
MX375934B (es) 2025-03-07
ES2902456T3 (es) 2022-03-28
RU2702361C2 (ru) 2019-10-08
CA2928364C (en) 2021-11-23
CN106102741A (zh) 2016-11-09
AU2014338612C1 (en) 2020-09-24
RU2016115376A3 (enExample) 2018-07-02
US9827235B2 (en) 2017-11-28
JP2019116508A (ja) 2019-07-18
HUE057504T2 (hu) 2022-05-28
MX2016005161A (es) 2016-10-05
EP3060213A1 (en) 2016-08-31
JP2016538258A (ja) 2016-12-08
BR112016008979B1 (pt) 2023-04-25
EP3060213B1 (en) 2021-10-13
JP6886996B2 (ja) 2021-06-16

Similar Documents

Publication Publication Date Title
AP2016009275A0 (enExample)
BR112015007533A2 (enExample)
BR112016014317A2 (enExample)
BR102016010778A2 (enExample)
BR112014017733A2 (enExample)
BR112014017739A2 (enExample)
BR112014018502A2 (enExample)
BR112014018516A2 (enExample)
BR112014017765A2 (enExample)
BR112014018480A2 (enExample)
BR112014017855A2 (enExample)
BR112014020341A2 (enExample)
BR112014017901A2 (enExample)
BR112014018483A2 (enExample)
BR112014017722A2 (enExample)
BR112014017794A2 (enExample)
BR112014018578A2 (enExample)
BR112016012619A2 (enExample)
BR112014017601A2 (enExample)
BR112015015312A2 (enExample)
BR112014024039A2 (enExample)
BR112014018496A2 (enExample)
BR112015027727A2 (enExample)
BR112014018437A2 (enExample)
BR112014017992A2 (enExample)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/10/2014, OBSERVADAS AS CONDICOES LEGAIS